Editas Medicine, Inc.EDIT

Editas Medicine, Inc. Leases Disclosure

10-KFiled Mar 9, 20262 min read
Leases
The Company has multiple lease agreements for office, laboratory, and manufacturing space with varying contractual terms set to expire between 2026 and 2028. Typically, base rent payments commence at the beginning of each lease term and continue through the term of the respective lease. The Company’s lease agreements have escalating rent clauses, which require higher rent payments in future years. The Company has one significant lease for office and laboratory space located in Cambridge, Massachusetts. The term of the lease began on October 1, 2016 and continues until October 2028. The Company does not have the option to extend the term of the lease at the termination date.
In 2023, the Company entered into a license and service agreement under which it leased manufacturing space for its continued research and development activities to support the Company’s former reni-cel program. The lease commenced on April 1, 2024. In January 2025, the Company provided termination notice for the license and service agreement, which resulted in a scheduled lease termination date in July 2026 and $8.9 million of remaining payments owed. In April 2025, the Company entered into a modification to the lease to accelerate the lease termination date to April 30, 2025 with a final fixed payment of $3.7 million. As the lease modification resulted from the Discontinuation, as defined in Note 17, Restructuring and Impairment Charges, the Company recorded an expense for the final fixed payment in restructuring and impairment charges in the consolidated statement of operations during the year ended December 31, 2025.
The Company’s operating leases included in its consolidated balance sheets as follows (in thousands):
As of
December 31,
2025		December 31,
2024
Right-of-use assets$16,121 $32,554 
Operating lease liabilities, current$(6,031)$(14,652)
Operating lease liabilities, non-current$(12,071)$(20,380)
During the years ended December 31, 2025 and 2024, the Company recorded $14.8 million and $21.0 million, respectively, of expense related to operating lease costs and $2.6 million and $2.8 million, respectively, related to variable costs associated with the Company’s operating leases.
Maturities of the Company’s lease liabilities as of December 31, 2025 were as follows (in thousands):
Maturity of lease liabilities:Year Ended
December 31, 2025
2026$7,389 
2027$7,076 
2028$6,000 
Total minimum lease payments$20,465 
Less: imputed interest$(2,363)
Total operating lease liabilities at December 31, 2025$18,102 
The weighted-average remaining lease term is 2.8 years and the weighted-average discount rate is 9.2%.
Free Sentinel

Want the next Editas Medicine, Inc. leases disclosure the moment it drops?

Set a Sentinel and we'll alert you the moment Editas Medicine, Inc.'s next filing hits EDGAR. No credit card, your email never gets sold.

Track for free

Historical Timeline

Fiscal YearFiled
2025Mar 9, 2026Showing above
2024Mar 5, 2025
2023Feb 28, 2024
2022Feb 22, 2023
2021Feb 24, 2022
2020Feb 26, 2021

About Leases Disclosures

Lease disclosures under ASC 842 provide a comprehensive view of a company's leased asset portfolio, including the split between operating and finance leases, discount rates used to present-value future payments, and the maturity schedule of lease obligations. This section reveals a significant source of off-balance-sheet commitments that were largely hidden before the current standard.

Key signals: the weighted-average discount rate affects the size of recorded lease liabilities — a higher rate reduces the reported obligation, so compare the chosen rate against the company's incremental borrowing rate. The operating versus finance lease mix affects both EBITDA and operating income presentation. Watch the maturity table for concentration risk: large payment cliffs in specific years may create cash flow pressure. Variable lease payments excluded from the liability measurement represent real obligations that do not appear on the balance sheet. Compare total lease costs against prior-year operating lease expense to assess the true economic burden.

Other Available Disclosures

Income TaxesEarnings Per ShareFair ValuePP&ESegmentsDebtCommitmentsStock CompensationNew StandardsPay vs Performance